CTS (CTS) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
28 Jul, 2026Business overview and market positioning
Designs and manufactures custom engineered solutions for sensing, connectivity, and motion across global markets, with $564M in LTM revenue and 24% adjusted EBITDA margin.
Revenue is diversified: 42% transportation, 27% industrial, 17% medical, and 14% aerospace & defense, with 58% now from non-transportation markets.
Technical expertise in advanced ceramics, magnetics, piezoelectric ceramics, and acoustic sensing underpins sustainable competitive advantage.
Growth driven by automation, healthcare innovation, electrification, and sustainability trends.
Global footprint with regional capabilities and a strong leadership team focused on operational excellence.
Financial performance and targets
LTM adjusted diluted EPS reached $2.58, with a long-term target of 10% annual revenue growth.
Adjusted gross margin at 39.8%, SG&A at 18.0%, and R&D expense at 4.3% of sales, aligning with long-term targets.
FY 2026 revenue guidance is $565–$585M, with adjusted diluted EPS of $2.55–$2.70.
Free cash flow for 2025 was $86.4M, with strong cash conversion and $314M returned to shareholders since 2013.
Maintains leverage of 1.0–2.5x and targets capex at ~4% of sales.
Growth strategy and capital allocation
Pursues mid-single digit organic growth and strategic M&A, aiming for 10% combined annual growth.
M&A strategy focuses on enhancing technology, expanding geographies, and entering new end markets, with disciplined ROI above cost of capital.
Capital allocation prioritizes organic investments, operational excellence, and shareholder returns through dividends and repurchases.
Evolution 2030 initiative emphasizes growth, operational excellence, and talent engagement.
Latest events from CTS
- Record Q2 2026 margins, 7% revenue growth, and raised outlook driven by diversified markets.CTS
Q2 202628 Jul 2026 - Q4 revenue up 9% with strong diversified growth; 2026 outlook remains positive.CTS
Q4 20259 Jul 2026 - Q3 2024 saw higher margins and EPS, with diversified growth offsetting transportation declines.CTS
Q3 20248 Jul 2026 - Medical, industrial, and defense growth outpace automotive, with strong margins and disciplined M&A.CTS
16th Annual East Coast IDEAS Conference11 Jun 2026 - Q1 2026 delivered 11% sales growth, margin expansion, and robust earnings improvement.CTS
Q1 202630 Apr 2026 - Diversified growth and innovation support strong financial outlook and long-term expansion.CTS
Investor presentation29 Apr 2026 - 2025 saw diversified growth, strong cash flow, and continued focus on governance and ESG.CTS
Proxy filing2 Apr 2026 - Votes will be cast on directors, executive pay, and auditor ratification at the 2026 meeting.CTS
Proxy filing2 Apr 2026 - Q2 2024 sales fell 10% year-over-year, but net income and defense diversification improved.CTS
Q2 20242 Feb 2026